<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02606500</url>
  </required_header>
  <id_info>
    <org_study_id>Merck-01</org_study_id>
    <nct_id>NCT02606500</nct_id>
  </id_info>
  <brief_title>Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success</brief_title>
  <official_title>Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to determine, whether clinical efficacy of 150 mcg of
      Corifollitropin alfa is the same in normal weighing and obese women. Furthermore,
      investigators want to determine whether oocytes retrieved from normal weighing and obese
      women, after COH using 150 mcg of Corifollitropin alfa, are of same quality on the molecular
      level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dosage of Corifollitropin alfa used for controlled ovarian hyperstimulation (COH) is
      adjusted according to the patient's body weight. Meaning, in women with a body weight ≤ 60
      kg, a single dose of 100 mcg of Corifollitropin alfa is administered for COH and in women
      with a body weight &gt; 60 kg, a single dose of 150 micrograms of Corifollitropin alfa is
      administered for COH. These two protocols are comparable in safety and efficacy of follicular
      stimulation.

      On the other hand, knowledge about the clinical efficacy of 150 mcg of Corifollitropin alfa
      in obese women (BMI&gt;30 kg/m2) is lacking.

      Cumulus cells (CC) surround the oocyte and bi-directional communication between oocyte and CC
      is necessary for the development of mature and quality oocytes. It has been proposed, that
      analysis of genes, expressed in CC, can serve as an objective indicator of the oocyte's
      maturity and developmental potential. Expression of genes in CC as hyaluronan synthase 2
      (HAS2), follicle-stimulating hormone receptor (FSHR), versican (VCAN), progesterone receptor
      (PR), vascular endothelial growth factor C (VEGFC), serine protease inhibitor E2 (SERPINE2),
      glutathione peroxidase (GPX3), pentraxin 3(PTX3) was reported to correlate with oocyte
      maturity and developmental potential.

      The effect of Corifollitropin alfa on expression of these genes however, is unknown.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes retrieved and pregnancies achieved when corifollitropin alpha is used for ovarian stimulation in obese women</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of genes that were proposed as biomarkers of oocyte quality to determine effect of corifollitropin alpha on oocyte quality on molecular level</measure>
    <time_frame>12 months</time_frame>
    <description>Expression of genes that were proposed as biomarkers of oocyte quality will be analysed using real-time PCR. Relative expression values of genes will be compared between oocytes derived from obese women and oocytes derived from normal weighing women.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Elonva 150 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elonva 150 mcg intramuscular daily obese</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elonva 100 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Elonva 100 mcg intramuscular daily normal weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elonva</intervention_name>
    <description>20 obese women will be the study group and 20 normal weighing women will be the control group. Both groups will receive 150 mcg of Elonva for controlled ovarian hyperstimulation (COH). GnRH antagonist will be used to prevent premature LH surge. Additional daily doses of 200 IU of rFSH will be used if necessary. hCG will be used for oocyte maturation. 2 mature follicles will be aspirated separately in each patient. CC samples will be collected and stored on -80 oC for subsequent analysis. Clinical and molecular parameters of IVF success will be assessed and compared between the groups.
The exclusion criteria will be: polycystic ovary syndrome, severely abnormal sperm parameters, and age &gt; 38 years.</description>
    <arm_group_label>Elonva 150 mcg</arm_group_label>
    <arm_group_label>Elonva 100 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt; 30 kg/m2

          -  BMI 18.5-24.9 kg/m2

        Exclusion Criteria:

          -  polycystic ovary syndrome, severely abnormal sperm parameters, and age &gt; 38 years
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eda Vrtacnik Bokal, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Head of the department of Human reproduction</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eda Vrtacnik Bokal, professor</last_name>
    <phone>+38615226002</phone>
    <email>eda.bokal@guest.arnes.si</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of gynecology, Department of human reproduction</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eda Vrtacnik Bokal, professor</last_name>
      <email>eda.bokal@guest.arnes.si</email>
    </contact>
    <contact_backup>
      <last_name>Tanja Burnik Papler, MD, PhD</last_name>
      <email>tanja.papler@icloud.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <reference>
    <citation>Burnik Papler T, Vrtacnik Bokal E, Maver A, Kopitar AN, Lovrečić L. Transcriptomic Analysis and Meta-Analysis of Human Granulosa and Cumulus Cells. PLoS One. 2015 Aug 27;10(8):e0136473. doi: 10.1371/journal.pone.0136473. eCollection 2015.</citation>
    <PMID>26313571</PMID>
  </reference>
  <reference>
    <citation>Burnik Papler T, Vrtačnik Bokal E, Maver A, Lovrečić L. Specific gene expression differences in cumulus cells as potential biomarkers of pregnancy. Reprod Biomed Online. 2015 Apr;30(4):426-33. doi: 10.1016/j.rbmo.2014.12.011. Epub 2015 Jan 12.</citation>
    <PMID>25682305</PMID>
  </reference>
  <reference>
    <citation>Burnik Papler T, Vrtacnik Bokal E, Lovrecic L, Kopitar AN, Maver A. No specific gene expression signature in human granulosa and cumulus cells for prediction of oocyte fertilisation and embryo implantation. PLoS One. 2015 Mar 13;10(3):e0115865. doi: 10.1371/journal.pone.0115865. eCollection 2015.</citation>
    <PMID>25769026</PMID>
  </reference>
  <reference>
    <citation>Devjak R, Fon Tacer K, Juvan P, Virant Klun I, Rozman D, Vrtačnik Bokal E. Cumulus cells gene expression profiling in terms of oocyte maturity in controlled ovarian hyperstimulation using GnRH agonist or GnRH antagonist. PLoS One. 2012;7(10):e47106. doi: 10.1371/journal.pone.0047106. Epub 2012 Oct 17.</citation>
    <PMID>23082142</PMID>
  </reference>
  <reference>
    <citation>Vrtacnik-Bokal E, Virant Klun I, Verdenik I. Follicular oestradiol and VEGF after GnRH antagonists or GnRH agonists in women with PCOS. Reprod Biomed Online. 2009 Jan;18(1):21-8.</citation>
    <PMID>19146765</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Tanja Burnik Papler</investigator_full_name>
    <investigator_title>Principal investigator Tanja Burnik Papler, MD; PhD</investigator_title>
  </responsible_party>
  <pending_results>
    <submitted>August 30, 2017</submitted>
    <returned>April 5, 2018</returned>
    <submitted>May 2, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

